gptkbp:instanceOf
|
gptkb:chemical_compound
|
gptkbp:ATCCode
|
N05CD11
|
gptkbp:CASNumber
|
77472-71-0
|
gptkbp:drugClass
|
prodrug
benzodiazepine derivative
|
gptkbp:hasInChIKey
|
QZQXKZBHZHPSDF-UHFFFAOYSA-N
|
gptkbp:hasMolecularFormula
|
C17H19N3O3
|
gptkbp:hasSMILES
|
CCOC(=O)NC1=NC2=C(C=C(C=C2)Cl)C(=O)N(C1)C3=CC=CC=N3
|
gptkbp:hasTherapeuticUse
|
sedative
hypnotic
|
gptkbp:hasYearOfFirstApproval
|
1984
|
https://www.w3.org/2000/01/rdf-schema#label
|
CHEMBL39122
|
gptkbp:isApprovedDrugIn
|
gptkb:Japan
|
gptkbp:isMetabolizedTo
|
gptkb:N-desmethylrilmazolam
gptkb:desmethylrilmazafone
rilmazolam
|
gptkbp:IUPACName
|
gptkb:ethyl_7-chloro-5-(2-pyridyl)-3H-1,4-benzodiazepin-2-one-4-ylcarbamate
|
gptkbp:legalStatus
|
prescription only (Japan)
|
gptkbp:molecularWeight
|
313.35
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL39122
5282432
DB13697
|
gptkbp:routeOfAdministration
|
oral
|
gptkbp:sideEffect
|
nausea
dizziness
headache
drowsiness
ataxia
|
gptkbp:synonym
|
gptkb:Rilmazafone
|
gptkbp:target
|
gptkb:GABAA_receptor
|
gptkbp:bfsParent
|
gptkb:DMT
|
gptkbp:bfsLayer
|
7
|